Blog

AIS 2025 in France showcased innovation in antibody science. Biointron reports highlights advancing discovery, engineering, and therapeutic development.

Boston’s 2025 Antibody & ADC Therapeutics Xchanges gathered global leaders. Biointron highlights collaborative insights shaping the future of antibody therapies.

BIO 2025 in Boston featured global biotech innovation. Biointron highlights conference insights advancing antibody discovery and development.

World ADC Asia 2025 in South Korea showcased next-gen ADCs. Biointron reports event highlights shaping oncology therapeutics.

AET Europe 2025 in Switzerland highlighted antibody engineering. Biointron shares key takeaways on discovery and development advances.

CHO, HEK293, and NS0 cells power antibody production. Biointron compares their pros and cons for scalable biomanufacturing.

Antibody isotypes like IgG, IgA, and IgM serve unique roles. Biointron explains their classification and functions in immunity and medicine.

Polyclonal antibodies are diverse immune tools. Biointron reviews their characteristics and uses in diagnostics and research.

Affinity maturation sharpens antibody binding. Biointron explains its biological role in optimizing immune responses and therapies.

Antibody humanization reduces immune risk. Biointron highlights its significance for creating safe, effective therapeutic antibodies.

High-affinity antibodies improve drug efficacy. Biointron outlines strategies to boost binding strength and therapeutic outcomes.

Hybridoma cells revolutionized antibody production. Biointron explains their creation and importance in monoclonal antibody development.